Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline [Yahoo! Finance]
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: Yahoo! Finance
now . The company's lead program, CTX-009, is progressing through clinical trials for advanced solid tumors, particularly biliary tract cancer (BTC), where the company estimates a market opportunity exceeding $1 billion. Notably, Compass Therapeutics Inc. (NASDAQ:CMPX) is pointing out a significant unmet medical need, as around 85% of BTC patients who fail first-line therapy have no approved, effective treatment. Guggenheim Sees Compass (CMPX) Potential Driven by Biliary Tract Cancer Pipeline Pressmaster/Shutterstock.com On that front, analyst Michael Schmidt of Guggenheim released an optimistic report. On August 12, the analyst raised his price target on Compass Therapeutics Inc. (NASDAQ:CMPX) to $12 from $10, and maintained a Buy rating. The call followed the release of Q2 results, which included encouraging pipeline updates and new clinical data. Management updated guidance for the COMPANION-002 Phase 2/3 trial of tovecimig in biliary tract cancer. Final progression-free su
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Citizens Jmp. They set an "outperform" rating and a $10.00 price target on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- Compass Therapeutics (NASDAQ:CMPX) was given a new $10.00 price target on by analysts at JMP Securities.MarketBeat
CMPX
Earnings
- 8/11/25 - Miss
CMPX
Sec Filings
- 11/18/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- CMPX's page on the SEC website